Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB9 hours ago · Sept. 27, 2024. West Coast Biotech & Life Sciences Reporter. Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of ...
Dupixent approved in the US as the first-ever biologic medicine …
WEB23 hours ago · Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB9 hours ago · Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB9 hours ago · They based their figure on 30% uptake of the treatment for those who are eligible. The addition would put Dupixent’s sales potential at $20 billion by the end of this decade, making it one of ...
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB4 hours ago · Treatment with Dupixent was shown to reduce COPD exacerbations by 30% in the BOREAS trial and by 34% in the NOTUS trial over 52 weeks. Additionally, the biologic was associated with improvements ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB9 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said ...
Press Release: Dupixent approved in the US as the first-ever …
WEB9 hours ago · Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB23 hours ago · European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic …
WEB8 hours ago · Sanofi claimed that Dupixent will be nation's first biologic medicine approved for these conditions. COPD is a respiratory disease that damages the lungs and causes progressive lung function decline.
FDA Approves Dupilumab as First Biologic Treatment for COPD
WEB8 hours ago · Dupixent approved in China as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (COPD). September 27, 2024. Accessed September 27, 2024.